Fig 1: miR-197 inhibits the activity, migration and invasion of GC cells by decreasing CXCR6 and Beclin1 expression levels. (A) CXCR6 and (B) Beclin1 expression levels in NCL-N87 cells were assessed using reverse transcription-quantitative PCR. (C) CXCR6 and (D) Beclin1 expression levels were measured using western blot analysis. (E) Viability of NCL-N87 and MKN-45 cells was determined using a Cell Counting Kit-8 assay. (F) Migration of NCL-N87 and MKN-45 cells was measured via wound healing test (magnification, ×200). (G) Invasion of NCL-N87 and MKN-45 cells was evaluated using Transwell assays (magnification, ×200). *P<0.05. miR, microRNA; JPX, long non-coding RNA JPX transcript, XIST activator; NC, negative control; CXCR6, C-X-C motif chemokine receptor 6; OD, optical density.
Fig 2: miR-197 directly inhibits CXCR6 expression and autophagy. (A) Starbase predicted the binding site between miR-197 and CXCR6. (B) Luciferase reporter gene assay was conducted to investigate the relationship between miR-197 and CXCR6. (C) miR-197 and CXCR6 expression levels in NCL-N87 cells were assessed via reverse transcription-quantitative PCR. (D) CXCR6, (E) LC3-II, LC3-I, Beclin1 and p62 protein expression levels were determined using western blotting. *P<0.05. miR, microRNA; JPX, long non-coding RNA JPX transcript, XIST activator; NC, negative control; CXCR6, C-X-C motif chemokine receptor 6.
Supplier Page from Abcam for Anti-CXCR6 antibody [EPR9086]